MA50071A - Polythérapies pour des individus atteints d'une infection au virus de l'hépatite b (vhb) utilisant parapoxvirus ovis (ppvo) et au moins un autre médicament antiviral - Google Patents

Polythérapies pour des individus atteints d'une infection au virus de l'hépatite b (vhb) utilisant parapoxvirus ovis (ppvo) et au moins un autre médicament antiviral

Info

Publication number
MA50071A
MA50071A MA050071A MA50071A MA50071A MA 50071 A MA50071 A MA 50071A MA 050071 A MA050071 A MA 050071A MA 50071 A MA50071 A MA 50071A MA 50071 A MA50071 A MA 50071A
Authority
MA
Morocco
Prior art keywords
polytherapies
ppvo
hbv
hepatitis
individuals
Prior art date
Application number
MA050071A
Other languages
English (en)
Inventor
Ibironke Addy
Stephan Menne
Daniela Paulsen
Tamara Pfaff
Willem Sloot
Andreas Urban
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of MA50071A publication Critical patent/MA50071A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA050071A 2017-09-07 2018-09-07 Polythérapies pour des individus atteints d'une infection au virus de l'hépatite b (vhb) utilisant parapoxvirus ovis (ppvo) et au moins un autre médicament antiviral MA50071A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189890 2017-09-07
EP17196684 2017-10-16

Publications (1)

Publication Number Publication Date
MA50071A true MA50071A (fr) 2020-07-15

Family

ID=63442656

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050071A MA50071A (fr) 2017-09-07 2018-09-07 Polythérapies pour des individus atteints d'une infection au virus de l'hépatite b (vhb) utilisant parapoxvirus ovis (ppvo) et au moins un autre médicament antiviral

Country Status (20)

Country Link
US (1) US20200261520A1 (fr)
EP (1) EP3678697A1 (fr)
JP (2) JP2020533314A (fr)
KR (1) KR20200051685A (fr)
CN (1) CN111093697A (fr)
AU (1) AU2018327688B2 (fr)
BR (1) BR112020004539A2 (fr)
CA (1) CA3075206A1 (fr)
CL (1) CL2020000556A1 (fr)
CU (1) CU20200016A7 (fr)
EC (1) ECSP20016672A (fr)
GE (1) GEP20237518B (fr)
IL (1) IL273093A (fr)
MA (1) MA50071A (fr)
MX (1) MX2020002605A (fr)
PH (1) PH12020500445A1 (fr)
SG (1) SG11202001931WA (fr)
TW (1) TW201919675A (fr)
UY (1) UY37869A (fr)
WO (1) WO2019048640A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3906970T3 (pl) * 2020-05-08 2022-10-24 Aicuris Gmbh & Co. Kg Parapokswirus do kondycjonowania i leczenia zakażeń koronawirusowych
EP3906929A1 (fr) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir pour son utilisation dans la prévention et le traitement des infections à coronavirus
WO2021242850A1 (fr) * 2020-05-28 2021-12-02 The Regents Of The University Of Michigan Compositions et méthodes permettant de prévenir et de traiter une infection par sars-cov-2
WO2023083943A1 (fr) 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus pour la préparation à des infections virales respiratoires et le traitement de telles infections en combinaison avec des antiviraux
WO2023083951A1 (fr) 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus pour la préparation et le traitement d'infections par le virus respiratoire syncytial
WO2023083950A1 (fr) 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus pour la préparation à des infections virales respiratoires et le traitement de telles infections en combinaison avec des immunomodulateurs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1303286B1 (fr) * 2000-07-11 2006-04-26 Bayer HealthCare AG Utilisation de souches du virus parapox ovis pour la fabrication de medicaments antiviraux et anticancereux
CZ200372A3 (cs) * 2000-07-11 2003-05-14 Bayer Aktiengesellschaft Použití kmenů Parapoxvirus ovis pro výrobu léku k léčení orgánových fibróz
BRPI0513321B1 (pt) * 2004-07-13 2022-03-08 Aicuris Gmbh & Co. Kg Vírus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais
CA2633400A1 (fr) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryle-uree pour le traitement d'infections virales
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
WO2017015451A1 (fr) * 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b

Also Published As

Publication number Publication date
UY37869A (es) 2019-04-30
GEP20237518B (en) 2023-07-10
CL2020000556A1 (es) 2020-09-04
SG11202001931WA (en) 2020-04-29
CA3075206A1 (fr) 2019-03-14
MX2020002605A (es) 2020-07-20
JP2022167901A (ja) 2022-11-04
US20200261520A1 (en) 2020-08-20
IL273093A (en) 2020-04-30
CU20200016A7 (es) 2020-11-30
WO2019048640A1 (fr) 2019-03-14
ECSP20016672A (es) 2020-06-30
TW201919675A (zh) 2019-06-01
AU2018327688A1 (en) 2020-03-19
KR20200051685A (ko) 2020-05-13
CN111093697A (zh) 2020-05-01
AU2018327688B2 (en) 2022-12-01
JP2020533314A (ja) 2020-11-19
BR112020004539A2 (pt) 2020-09-08
EP3678697A1 (fr) 2020-07-15
PH12020500445A1 (en) 2020-11-09

Similar Documents

Publication Publication Date Title
MA50071A (fr) Polythérapies pour des individus atteints d'une infection au virus de l'hépatite b (vhb) utilisant parapoxvirus ovis (ppvo) et au moins un autre médicament antiviral
MA50278A (fr) Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
MA45863A (fr) Agent arni contre l'infection par le virus de l'hépatite b
MA50520A (fr) Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
EP3426633A4 (fr) Élimination du virus de l'hépatite b par des agents antiviraux
MA46535A (fr) Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
CN106573011A8 (zh) 取代的核苷、核苷酸和其类似物
DK3043865T3 (da) Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
MA50524A (fr) Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
DK3166615T3 (da) Chelaterede phosphortioterede nukleinsyrepolymerer til anvendelse i kombination med en hbv-polymeraseinhibitor til behandlingen af hepatitis b- og hepatitis d-virusinfektioner
IL255366B (en) Reagents for the treatment of hepatitis B infection and their use
PT3416675T (pt) Tratamento de infeção pelo vírus da hepatite delta com interferão lambda
MA52661A (fr) Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
MA51292A (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
MA45088A (fr) Méthodes pour traiter des infections par le virus de l'hépatite b au moyen d'inhibiteurs de ns5a, ns5b ou ns3
EA201790778A1 (ru) Фармацевтические композиции длительного действия от гепатита с
EP3641772A4 (fr) Traitement du carcinome hépatocellulaire caractérisé par une infection par le virus de l'hépatite b
EA201692507A1 (ru) Фармацевтические комбинации софосбувира и рибавирина
EP3452595A4 (fr) Réactifs pour le traitement d'infection par le virus de l'hépatite b (vhb) et utilisation de ceux-ci
MX2018000213A (es) Metodos para tratar el vhc.
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
IL286484B (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
LeLacheur HIV Infection What Primary Care Providers Need to Know.
WO2016036252A3 (fr) Anticorps spécifique du virus de l'hépatite c